MONUROL POWDER FOR SOLUTION Canada - English - Health Canada

monurol powder for solution

paladin labs inc. - fosfomycin (fosfomycin tromethamine) - powder for solution - 3g - fosfomycin (fosfomycin tromethamine) 3g - urinary anti-infectives

IVOZFO POWDER FOR SOLUTION Canada - English - Health Canada

ivozfo powder for solution

verity pharmaceuticals inc. - fosfomycin (fosfomycin sodium) - powder for solution - 2g - fosfomycin (fosfomycin sodium) 2g - urinary anti-infectives

IVOZFO POWDER FOR SOLUTION Canada - English - Health Canada

ivozfo powder for solution

verity pharmaceuticals inc. - fosfomycin (fosfomycin sodium) - powder for solution - 4g - fosfomycin (fosfomycin sodium) 4g - urinary anti-infectives

IVOZFO POWDER FOR SOLUTION Canada - English - Health Canada

ivozfo powder for solution

verity pharmaceuticals inc. - fosfomycin (fosfomycin sodium) - powder for solution - 8g - fosfomycin (fosfomycin sodium) 8g - urinary anti-infectives

FOMICYT 2 G. Israel - English - Ministry of Health

fomicyt 2 g.

tzamal bio-pharma ltd - fosfomycin as sodium - powder for solution for infusion - fosfomycin as sodium 2 g - fosfomycin - fomicyt is indicated in all age groups for the treatment of the following infections when it is considered inappropriate to use antibacterial agents that are commonly recommended for their initial treatment:• complicated urinary tract infections• infective endocarditis• bone and joint infections• hospital-acquired pneumonia, including ventilator-associated pneumonia• complicated skin and soft tissue infection• bacterial meningitis• complicated intra-abdominal infections• bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed aboveconsideration should be given to official guidance on the appropriate use of antibacterial agents.

FOMICYT 4 G. Israel - English - Ministry of Health

fomicyt 4 g.

tzamal bio-pharma ltd - fosfomycin as sodium - powder for solution for infusion - fosfomycin as sodium 4 g - fosfomycin - fomicyt is indicated in all age groups for the treatment of the following infections when it is considered inappropriate to use antibacterial agents that are commonly recommended for their initial treatment:• complicated urinary tract infections• infective endocarditis• bone and joint infections• hospital-acquired pneumonia, including ventilator-associated pneumonia• complicated skin and soft tissue infection• bacterial meningitis• complicated intra-abdominal infections• bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed aboveconsideration should be given to official guidance on the appropriate use of antibacterial agents.